Item request has been placed!
×
Item request cannot be made.
×
Processing Request
A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Source:
PLoS biology [PLoS Biol] 2022 Aug 09; Vol. 20 (8), pp. e3001721. Date of Electronic Publication: 2022 Aug 09 (Print Publication: 2022).
- Publication Type:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
- Language:
English
- Additional Information
- Corporate Authors:
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101183755 Publication Model: eCollection Cited Medium: Internet ISSN: 1545-7885 (Electronic) Linking ISSN: 15449173 NLM ISO Abbreviation: PLoS Biol Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science, [2003]-
- Subject Terms:
- Abstract:
The Comprehensive Resistance Prediction for Tuberculosis: an International Consortium (CRyPTIC) presents here a data compendium of 12,289 Mycobacterium tuberculosis global clinical isolates, all of which have undergone whole-genome sequencing and have had their minimum inhibitory concentrations to 13 antitubercular drugs measured in a single assay. It is the largest matched phenotypic and genotypic dataset for M. tuberculosis to date. Here, we provide a summary detailing the breadth of data collected, along with a description of how the isolates were selected, collected, and uniformly processed in CRyPTIC partner laboratories across 23 countries. The compendium contains 6,814 isolates resistant to at least 1 drug, including 2,129 samples that fully satisfy the clinical definitions of rifampicin resistant (RR), multidrug resistant (MDR), pre-extensively drug resistant (pre-XDR), or extensively drug resistant (XDR). The data are enriched for rare resistance-associated variants, and the current limits of genotypic prediction of resistance status (sensitive/resistant) are presented by using a genetic mutation catalogue, along with the presence of suspected resistance-conferring mutations for isolates resistant to the newly introduced drugs bedaquiline, clofazimine, delamanid, and linezolid. Finally, a case study of rifampicin monoresistance demonstrates how this compendium could be used to advance our genetic understanding of rare resistance phenotypes. The data compendium is fully open source and it is hoped that it will facilitate and inspire future research for years to come.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: E.R. is employed by Public Health England and holds an honorary contract with Imperial College London. I.F.L. is Director of the Scottish Mycobacteria Reference Laboratory. S.N. receives funding from German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG)tion EXC 2167. P.S. is a consultant at Genoscreen. T.R. is funded by NIH and DoD and receives salary support from the non-profit organization FIND. T.R. is a co-founder, board member and shareholder of Verus Diagnostics Inc, a company that was founded with the intent of developing diagnostic assays. Verus Diagnostics was not involved in any way with data collection, analysis or publication of the results. T.R. has not received any financial support from Verus Diagnostics. UCSD Conflict of Interest office has reviewed and approved T.R.’s role in Verus Diagnostics Inc. T.R. is a co-inventor of a provisional patent for a TB diagnostic assay (provisional patent #: 63/048.989). T.R. is a co-inventor on a patent associated with the processing of TB sequencing data (European Patent Application No. 14840432.0 & USSN 14/912,918). T.R. has agreed to “donate all present and future interest in and rights to royalties from this patent” to UCSD to ensure that he does not receive any financial benefits from this patent. S.S. is working and holding ESOPs at HaystackAnalytics Pvt. Ltd. (Product: Using whole genome sequencing for drug susceptibility testing for Mycobacterium tuberculosis). G.F.G. is listed as an inventor on patent applications for RBD-dimer-based CoV vaccines. The patents for RBD-dimers as protein subunit vaccines for SARS-CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China.
- References:
J Antimicrob Chemother. 2017 Aug 1;72(8):2326-2333. (PMID: 28535203)
Bioinformatics. 2002 Nov;18(11):1546-7. (PMID: 12424131)
Science. 2008 Nov 28;322(5906):1392-5. (PMID: 19039139)
Int J Infect Dis. 2014 Sep;26:149-53. (PMID: 25086437)
Expert Rev Mol Diagn. 2015 Jan;15(1):9-22. (PMID: 25373876)
BMJ Open. 2019 Nov 6;9(11):e031663. (PMID: 31699736)
Lancet Microbe. 2020 Aug;1(4):e165-e174. (PMID: 32803174)
Genome Biol. 2022 Jul 5;23(1):147. (PMID: 35791022)
PLoS Biol. 2022 Aug 9;20(8):e3001755. (PMID: 35944070)
Eur Respir J. 2018 Mar 22;51(3):. (PMID: 29348152)
Front Microbiol. 2020 Sep 17;11:559469. (PMID: 33042066)
Elife. 2022 May 19;11:. (PMID: 35588296)
Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168)
N Engl J Med. 2015 Mar 19;372(12):1181-2. (PMID: 25785984)
Nat Commun. 2021 Oct 20;12(1):6099. (PMID: 34671035)
PLoS One. 2018 May 30;13(5):e0198091. (PMID: 29847567)
Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404)
Semin Immunol. 2014 Dec;26(6):431-44. (PMID: 25453224)
Wellcome Open Res. 2019 Dec 2;4:191. (PMID: 32055708)
Diagn Microbiol Infect Dis. 2016 Jun;85(2):177-81. (PMID: 27036978)
Microbiology (Reading). 2018 Dec;164(12):1522-1530. (PMID: 30351270)
Lancet Respir Med. 2016 Jan;4(1):49-58. (PMID: 26669893)
Eur Respir J. 2012 Oct;40(4):814-22. (PMID: 22653774)
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0036421. (PMID: 34460307)
Antimicrob Agents Chemother. 2010 Mar;54(3):1022-8. (PMID: 20038615)
Curr Protoc Bioinformatics. 2020 Mar;69(1):e96. (PMID: 32162851)
Respir Med. 2017 Oct;131:43-48. (PMID: 28947041)
Genome Med. 2020 Nov 25;12(1):104. (PMID: 33239092)
Antimicrob Agents Chemother. 2013 Feb;57(2):893-900. (PMID: 23208715)
Antimicrob Agents Chemother. 2014 May;58(5):2979-81. (PMID: 24590481)
Antimicrob Agents Chemother. 2018 Feb 23;62(3):. (PMID: 29311078)
Nat Commun. 2024 Jan 12;15(1):488. (PMID: 38216576)
PLoS One. 2016 Apr 05;11(4):e0152933. (PMID: 27045684)
Nat Rev Microbiol. 2018 Apr;16(4):202-213. (PMID: 29456241)
Eur Respir J. 2017 May 21;49(5):. (PMID: 28529207)
PLoS Med. 2020 Jan 21;17(1):e1003008. (PMID: 31961877)
N Engl J Med. 2018 Oct 11;379(15):1403-1415. (PMID: 30280646)
Antimicrob Agents Chemother. 2018 Aug 27;62(9):. (PMID: 29941636)
Lancet Infect Dis. 2018 Dec;18(12):1350-1359. (PMID: 30342828)
Lancet. 2011 Apr 30;377(9776):1495-505. (PMID: 21507477)
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9. (PMID: 27185800)
Nat Genet. 2012 Jan 08;44(2):226-32. (PMID: 22231483)
Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943)
Eur Respir J. 2017 Dec 28;50(6):. (PMID: 29284687)
Am J Med Sci. 2013 Feb;345(2):143-8. (PMID: 22885627)
Eur Respir J. 2022 Oct 13;60(4):. (PMID: 35301246)
Lancet Respir Med. 2014 Apr;2(4):285-292. (PMID: 24717625)
- Grant Information:
U60 OE000103 United States OE OSELS CDC HHS; 214560/Z/18/Z United Kingdom WT_ Wellcome Trust; T32 GM007365 United States GM NIGMS NIH HHS; 203135/Z/16/Z United Kingdom WT_ Wellcome Trust; 098316 United Kingdom WT_ Wellcome Trust; 203141/Z/16/Z United Kingdom WT_ Wellcome Trust; R01 AI124413 United States AI NIAID NIH HHS; United Kingdom MRC_ Medical Research Council; 206724/Z/17/Z United Kingdom WT_ Wellcome Trust; R01 AI146338 United States AI NIAID NIH HHS; 201470/Z/16/Z United Kingdom WT_ Wellcome Trust; 101237/Z/13/B United Kingdom WT_ Wellcome Trust; 200205/Z/15/Z United Kingdom WT_ Wellcome Trust; 203583/Z/16/Z United Kingdom WT_ Wellcome Trust; BRC-1215-20008 United Kingdom DH_ Department of Health; FC0010218 United Kingdom WT_ Wellcome Trust; R01 AI114900 United States AI NIAID NIH HHS; United Kingdom WT_ Wellcome Trust; 214321/Z/18/Z United Kingdom WT_ Wellcome Trust; R03 AI117312 United States AI NIAID NIH HHS; FC0010218 United Kingdom CRUK_ Cancer Research UK
- Contributed Indexing:
Investigator: A Brankin; KM Malone; I Barilar; S Battaglia; E Borroni; AP Brandao; AM Cabibbe; J Carter; D Chetty; DM Cirillo; P Claxton; DA Clifton; T Cohen; J Coronel; DW Crook; V Dreyer; SG Earle; V Escuyer; L Ferrazoli; GF Gao; J Gardy; S Gharbia; KT Ghisi; A Ghodousi; AL Gibertoni Cruz; L Grandjean; C Grazian; R Groenheit; JL Guthrie; W He; H Hoffmann; SJ Hoosdally; M Hunt; NA Ismai; L Jarrett; L Joseph; R Jou; P Kambil; R Khot; J Knaggs; A Koch; D Kohlerschmidt; S Kouchaki; AS Lachapelle; A Lalvani; SG Lapierre; IF Laurenson; B Letcher; WH Lin; C Liu; D Liu; A Mandal; M Mansjo; D Matias; G Meintjes; FF Mendes; M Merker; M Mihalic; J Millard; P Miotto; N Mistry; D Moore; KA Musser; D Ngcamu; HN Nhung; S Niemann; KS Nilgiriwala; C Nimmo; M O’Donnell; N Ozoki; RS Oliveira; SV Omar; N Paton; TE Peto; JMW Pinhata; S Plesnik; ZM Puyen; MS Rabodoarivelo; N Rakotosamimanana; PM Rancoita; P Rathod; E Robinson; G Rodger; C Rodrigues; TC Rodwell; A Roohi; D Santos-Lazaro; S Shah; TA Kohl; G Smith; W Solano; A Spitaleri; P Supply; AJ Steyn; U Surve; S Tahseen; NTT Thuong; G Thwaites; K Todt; A Trovato; C Utpatel; A Van Rie; S Vijay; TM Walker; AS Walker; R Warren; J Werngren; M Wijkander; RJ Wilkinson; DJ Wilson; P Wintringer; YX Xiao; Y Yang; Z Yanlin; SY Yao; B Zhu; PW Fowler; Z Iqbal
- Accession Number:
0 (Antitubercular Agents)
VJT6J7R4TR (Rifampin)
- Publication Date:
Date Created: 20220809 Date Completed: 20220811 Latest Revision: 20240923
- Publication Date:
20240923
- Accession Number:
PMC9363010
- Accession Number:
10.1371/journal.pbio.3001721
- Accession Number:
35944069
No Comments.